By demonstrating a strong correlation between TRAF3IP2 expression and poorer clinical outcomes, we highlight the possibility that TRAF3IP2 contributes to both the aggressive phenotype and reduced survival rates characteristic of this breast cancer subtype (Fig. 1A-C). Here, TRAF3IP2 is linked to breast carcinoma.